Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 4, 2015, Pages 387-394

  Tang, Tao ^a   Liu, Jie ^a   Zuo, Keqiang ^a   Cheng, Jie ^a   Chen, Linyin ^b   Lu, Chenhui ^a   Han, Shilong ^a   Xu, Jichong ^a   Jia, Zhongzhi ^a   Ye, Meng ^a   Pei, Erli ^a   Zhang, Xiaoping ^a   Li, Maoquan ^a  

^a TONGJI UNIVERSITY   (China)

^b Tai Zhou Hospital of Zhejiang Province   (China)

Author keywords

anticoagulation; coumarin; genotype guided; meta analysis

Indexed keywords

COUMARIN; ACENOCOUMAROL; ANTICOAGULANT AGENT; PHENPROCOUMON; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DOSE RESPONSE; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; TREATMENT OUTCOME; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; PHARMACOGENETICS; STROKE; VENOUS THROMBOEMBOLISM;

ACENOCOUMAROL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; PHENPROCOUMON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84929608114     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414565666     Document Type: Article

References (40)

1. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 ; 119 (1 suppl). 8S - 21S
2. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013 ; 369 (24). 2304-2312
3. Levine MN, Rasko G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 ; 119 (1 suppl). 108S - 121S
4. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 ; 141 (10). 745-752
5. Schalekamp T, De Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des. 2010 ; 16 (2). 187-203
6. Glurich I, Burmester JK, Caldwell MD. Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev. 2010 ; 15 (3). 239-248
7. Limdi NA. Warfarin pharmacogenetics: challenges and opportunities for clinical translation. Front Pharmacol. 2012 ; 3: 183
8. Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005 ; 6 (5). 503-513
9. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 ; 360 (8). 753-764
10. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 ; 111 (8). 4106-4112
11. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 ; 90 (4). 625-629
12. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 ; 369 (24). 2294-2303
13. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 ; 116 (22). 2563-2570
14. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 ; 83 (3). 460-470
15. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012 ; 125 (16). 1997-2005
16. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009 ; 19 (3). 226-234
17. Kimmel SE, French B, Kasner SE, et al. Pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 ; 369 (24). 2283-2293
18. Jonas DE, Evans JP, McLeod HL, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013 ; 14 (13). 1593-1603
19. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med. 2011 ; 13 (6). 509-518
20. Verma S, Farkouh ME, Yanagawa B, et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2013 ; 1 (4). 317-328
21. Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001 ; 12 (3). 232-236
22. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007 ; 28 (2). 105-114
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327 (7414). 557-560
24. Connor KA. Quantifying associations: understanding relative risks and odds ratios. Pediatr Rev. 2012 ; 33 (10). 473-474
25. Caraco Y, Blotnick S, Muszkat M. CYP2C9genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 ; 83 (3). 460-470
26. Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT vs standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost. 2012 ; 108 (3). 561-569
27. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005 ; 3 (3). 137-145
28. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 ; 84 (3). 326-331
29. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract. 2009 ; 63 (10). 1426-1434
30. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006 ; 21 (1). 73-77
31. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141 (2 suppl). 7S - 47S
32. Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med. 2006 ; 48 (2). 182 189.e1-189
33. Alberts MJ. Genetics of warfarin dosing - one polymorphism at a time. Lancet. 2013 ; 382 (9894). 749-751
34. Johnson EG, Horne BD, Carlquist JF, Anderson JL. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations. Mol Diagn Ther. 2011 ; 15 (5). 255-264
35. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 ; 13 (287). 1690-1698
36. Nunnelee JD.. Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. J Vasc Nurs. 2009 ; 27 (4). 109
37. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009 ; 24 (5). 656-664
38. Shi XQ, Wang ZZ. Application of meta-regression and subgroup analyses of heterogeneity disposal in meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi. 2008 ; 29 (5). 497-501
39. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther. 2011 ; 89 (3). 408-415
40. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 ; 382 (9894). 790-796